Implementing new health initiatives in low-resource environments

Halving duration of ADT for high risk prostate cancer patients

Findings of a phase I/II study of nivolumab in patients with virus-associated tumours

New personalised therapies for lung cancer

Nivolumab and ipilimumab for metastatic sarcoma

Selumetinib in children with recurrent or refractory low-grade glioma

Dose escalation results of ceritinib and nivolumab for ALK NSCLC

Phase III results of olaparib for BRCA breast cancer

Global health initiative oncology

Self-reporting symptoms online improves patient care, chemotherapy duration and survival

Tivantinib as second line therapy for high-MET HCC

9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy